Amylin and Takeda End Development of Obesity Treatment

The firms say the decision to discontinue the program is based on a commercial reassessment, which included the evaluation of a revised development plan.

San Diego-based biopharmaceutical company Amylin Pharmaceuticals and its Japanese partner Takeda Pharmaceutical have decided to end development of the Phase II-stage obesity therapy candidate pramlintide/metreleptin.

The firms claim that the decision to discontinue the program is based on a commercial reassessment, which included the evaluation of a revised development plan. However, in March they suspended an ongoing Phase II trial evaluating pramlintide/metreleptin due to what was described as an antibody-related laboratory finding associated with metreleptin treatment in two patients who participated in a previously completed obesity clinical study.

Amylin and Takeda say they will continue to evaluate other assets for the potential treatment of obesity as part of their ongoing coll